Stephen J. Falk
Stephen J. Falk publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Surgery, on topics such as Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes and Colorectal Cancer Treatments and Studies.
- World rank
- #68,175 of 7,710,434 ranked researchers
- Rank in United Kingdom
- #5,784 of 367,258
- Works
- 220
- Citations
- 26k
- Citations per work
- 117.3
What does Stephen J. Falk research?
Stephen J. Falk's work is mostly in Medicine (70%), Biochemistry, Genetics and Molecular Biology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences15470.1%
- Medicine15470.1%
- Everything else5726.1%
- Life Sciences83.8%
- 1Oncology26% of their works
- 2Pulmonary and Respiratory Medicine20% of their works
- 3Surgery18% of their works
- 4Cancer Research4% of their works
- 5Radiology, Nuclear Medicine and Imaging3% of their works
- 6Pathology and Forensic Medicine3% of their works
Research topics
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
Which keywords describe Stephen J. Falk's research?
The keywords of their largest research topics: Chemotherapy, Neoadjuvant Therapy, Endoscopic Resection, Preoperative Chemoradiotherapy, Clinical Practice Guidelines, Epidemiology, Barrett's Esophagus and Esophageal Carcinoma.
- Biliary Tract Cancer
- Cancer Genomics
- Adjuvant Chemotherapy
- ALK Inhibitors
- Pancreatic Cancer
- Cetuximab
- Molecular Characterization
- Esophageal Carcinoma
- Epidemiology
- Preoperative Chemoradiotherapy
- Neoadjuvant Therapy
- Chemotherapy
- Endoscopic Resection
- Clinical Practice Guidelines
- Barrett's Esophagus
- Gastric Cancer
- Targeted Therapy
- KRAS Mutations
- Surgical Complications
- EGFR Mutations
- Rectal Cancer
- Mutational Signatures
- Cholangiocarcinoma
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Chemotherapy1473 topics
- Neoadjuvant Therapy1243 topics
- Endoscopic Resection1092 topics
- Preoperative Chemoradiotherapy802 topics
- Clinical Practice Guidelines792 topics
- Epidemiology712 topics
- Barrett's Esophagus551 topic
- Esophageal Carcinoma551 topic
- Gastric Cancer541 topic
- Molecular Characterization541 topic
- Targeted Therapy532 topics
- Cetuximab491 topic
- KRAS Mutations491 topic
- Pancreatic Cancer441 topic
- Surgical Complications441 topic
- ALK Inhibitors331 topic
- EGFR Mutations331 topic
- Adjuvant Chemotherapy251 topic
- Rectal Cancer251 topic
- Cancer Genomics201 topic
- Mutational Signatures201 topic
- Biliary Tract Cancer161 topic
- Cholangiocarcinoma161 topic
Where does Stephen J. Falk work?
Stephen J. Falk's main affiliation in the publication record is At Bristol, United Kingdom.
How many publications and citations does Stephen J. Falk have?
OpenAlex counts 220 works and 25,815 citations for Stephen J. Falk, an h-index of 58, ranking #68,175 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Stephen J. Falk. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.